WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H463832
CAS#: unknown
Description: P7 Peptide is a novel bFGF antagonist peptide, inhibiting breast cancer cell growth.
Hodoodo Cat#: H463832
Name: P7 Peptide
CAS#: unknown
Chemical Formula: C35H62N8O10
Exact Mass: 754.46
Molecular Weight: 754.927
Elemental Analysis: C, 55.69; H, 8.28; N, 14.84; O, 21.19
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: P7 Peptide; P7-Peptide; PLLQATL;
IUPAC/Chemical Name: L-prolyl-L-leucyl-L-leucyl-L-glutaminyl-L-alanyl-L-threonyl-L-leucine
InChi Key: MANFSJFEAFWUHW-UNRDKQAASA-N
InChi Code: InChI=1S/C35H62N8O10/c1-17(2)14-24(41-33(50)25(15-18(3)4)40-30(47)22-10-9-13-37-22)32(49)39-23(11-12-27(36)45)31(48)38-20(7)29(46)43-28(21(8)44)34(51)42-26(35(52)53)16-19(5)6/h17-26,28,37,44H,9-16H2,1-8H3,(H2,36,45)(H,38,48)(H,39,49)(H,40,47)(H,41,50)(H,42,51)(H,43,46)(H,52,53)/t20-,21+,22-,23-,24-,25-,26-,28-/m0/s1
SMILES Code: O=C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(N)=O)C(N[C@@H](C)C(N[C@@H]([C@H](O)C)C(N[C@@H](CC(C)C)C(O)=O)=O)=O)=O)=O)=O)[C@H]1NCCC1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 754.93 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Watson GM, Kulkarni K, Brandt R, Del Borgo MP, Aguilar MI, Wilce JA. Shortened Penetratin Cell-Penetrating Peptide Is Insufficient for Cytosolic Delivery of a Grb7 Targeting Peptide. ACS Omega. 2017 Feb 28;2(2):670-677. doi: 10.1021/acsomega.6b00561. Epub 2017 Feb 23. PMID: 29152602; PMCID: PMC5683694.
2: Chen X, Li L. [Non-membrane mechanisms of antimicrobial peptide P7 against Escherichia coli]. Wei Sheng Wu Xue Bao. 2016 Nov 4;56(11):1737-45. Chinese. PMID: 29741836.
3: Fan L, Li W, Ying S, Shi L, Wang Z, Chen G, Ye H, Wu X, Wu J, Liang G, Li X. A peptide derivative serves as a fibroblast growth factor 2 antagonist in human gastric cancer. Tumour Biol. 2015 Sep;36(9):7233-41. doi: 10.1007/s13277-015-3435-x. Epub 2015 Apr 19. PMID: 25894376.
4: Luo W, Yu Y, Wang R, He D, Wang C, Zeng X, Chen X, Tan X, Huang T, Wu X. P7 peptides targeting bFGF sensitize colorectal cancer cells to CPT-11. Int J Mol Med. 2014 Jan;33(1):194-200. doi: 10.3892/ijmm.2013.1547. Epub 2013 Nov 4. PMID: 24190390.
5: Li Q, Gao S, Yu Y, Wang W, Chen X, Wang R, Li T, Wang C, Li X, Wu X. A novel bFGF antagonist peptide inhibits breast cancer cell growth. Mol Med Rep. 2012 Jul;6(1):210-4. doi: 10.3892/mmr.2012.882. Epub 2012 Apr 20. PMID: 22576745.
6: Wang C, Yu Y, Li Q, Gao S, Jia X, Chen X, Wang R, Li T, Wang W, Li X, Wu X. P7 peptides suppress the proliferation of K562 cells induced by basic fibroblast growth factor. Tumour Biol. 2012 Aug;33(4):1085-93. doi: 10.1007/s13277-012-0348-9. Epub 2012 Feb 21. PMID: 22351562.
7: Jin S, Ellis E, Veetil JV, Yao H, Ye K. Visualization of human immunodeficiency virus protease inhibition using a novel Förster resonance energy transfer molecular probe. Biotechnol Prog. 2011 Jul;27(4):1107-14. doi: 10.1002/btpr.628. Epub 2011 May 16. PMID: 21584951; PMCID: PMC3163052.
8: Wu X, Yan Q, Huang Y, Huang H, Su Z, Xiao J, Zeng Y, Wang Y, Nie C, Yang Y, Li X. Isolation of a novel basic FGF-binding peptide with potent antiangiogenetic activity. J Cell Mol Med. 2010 Jan;14(1-2):351-6. doi: 10.1111/j.1582-4934.2008.00506.x. PMID: 20414975; PMCID: PMC3837584.
9: Griffin S, Clarke D, McCormick C, Rowlands D, Harris M. Signal peptide cleavage and internal targeting signals direct the hepatitis C virus p7 protein to distinct intracellular membranes. J Virol. 2005 Dec;79(24):15525-36. doi: 10.1128/JVI.79.24.15525-15536.2005. PMID: 16306623; PMCID: PMC1315988.
10: Cooperman BS, Gao Y, Tan C, Kashlan OB, Kaur J. Peptide inhibitors of mammalian ribonucleotide reductase. Adv Enzyme Regul. 2005;45:112-25. doi: 10.1016/j.advenzreg.2005.02.012. Epub 2005 Jul 28. PMID: 16054677.
11: Vilar M, Esteve V, Pallas V, Marcos JF, Perez-Paya E. Structural properties of carnation mottle virus p7 movement protein and its RNA-binding domain. J Biol Chem. 2001 May 25;276(21):18122-9. doi: 10.1074/jbc.M100706200. Epub 2001 Mar 5. PMID: 11279121.
12: Pender BA, Wu X, Axelsen PH, Cooperman BS. Toward a rational design of peptide inhibitors of ribonucleotide reductase: structure-function and modeling studies. J Med Chem. 2001 Jan 4;44(1):36-46. doi: 10.1021/jm000335r. PMID: 11141086.
13: Fruci D, Greco G, Vigneti E, Tanigaki N, Butler RH, Tosi R. The peptide- binding specificity of HLA-B27 subtype (B*2705) analyzed by the use of polyalanine model peptides. Hum Immunol. 1994 Sep;41(1):34-8. doi: 10.1016/0198-8859(94)90081-7. PMID: 7836062.
